Although the incidence of Pneumocystis pneumonia (PCP) has decreased since the
introduction of combination antiretroviral therapy, it remains an important cause of disease in …

Pneumocystis has gained attention during the last decade in the context of the AIDS
epidemic and the increasing use of cytotoxic and immunosuppressive therapies. The …

During the past 30 years, major advances have been made in our understanding of
HIV/AIDS and Pneumocystis pneumonia (PCP), but significant gaps remain. Pneumocystis …

Pneumocystis jirovecii is an atypical fungus exhibiting pulmonary tropism and a highly
defined host specificity. It is generally regarded as an opportunistic microorganism causing …

Pneumocystis jirovecii, formerly Pneumocystis carinii, has long been known to cause
disease in humans, particularly as an opportunistic pathogen of immunocompromised hosts …

Pneumocystis pneumonia (PCP) is well known and described in AIDS patients. Due to the
increasing use of cytotoxic and immunosuppressive therapies, the incidence of this infection …

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection diagnosed in
immunocompromized patients. After solid organ transplantation, early infection has …

Objectives First-line therapy for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim/
sulfamethoxazole. Few data exist to guide the choice of second-line therapy for patients …

Cinnamic acids are compounds of natural origin that can be found in many different parts of
a wide panoply of plants, where they play the most diverse biological roles, often in a …

Although combination therapy using trimethoprim–sulfamethoxazole (TMP–SMX) plus
echinocandins has been reported to reduce the mortality of patients with pneumocystis …